Weight Gain Management in Patients With Schizophrenia

• Patients, men or women, with age of 18 to 65 years
• Patients must have schizophrenia that meets disease diagnostic criteria as defined in DSM-IV Sections 295.10, 295.20, 295.30, or 295.90 and not to be in a clinically acute phase, in accordance with the judgment of the investigator
• Patients in use of 5 mg/day and 20 mg/day of olanzapine for a period not less than 2 months and not greater than 6 months and that have increased at least 5% of their corporal weight since the beginning of the treatment with olanzapine.
• The individuals must be trustworthy, and have a level of understanding enough to carry out all the tests and examinations demanded for the protocol, to understand the nature of the study and to have signed the informed consent
• Women with potential to become pregnant must be using a medically acceptable and reliable means of birth control.

Exclusion Criteria:

• Participation in a clinical study of another drug in investigation within a period of 1 month (30 days) before the entrance in the study (Visit 1)
• People who have used clozapine within a period of 12 months before the beginning of the study
• People with diagnosis of diabetes mellitus types I or II without adjusted clinical control or have initiated the medication use for glycemic control in the last 6 months
• DSM-IV substance (except nicotine and caffeine) dependence within the past 30 days
• Current participation in programs of weight loss